Hereditary spastic paraplegia is not a single disease but a group of inherited neurological conditions that share one defining feature: progressive stiffness and weakness in the legs caused by degeneration of the longest nerve fibers in the spinal cord. More than 80 genetic subtypes have been identified, and the condition can be inherited in almost every pattern known to genetics. Despite that genetic complexity, the core problem is remarkably consistent: the nerve fibers that carry movement signals from the brain to the lower limbs gradually break down, starting at their farthest ends.
What Goes Wrong in the Spinal Cord
The hallmark of HSP is damage to the corticospinal tracts, the bundles of nerve fibers (axons) that run from the brain’s motor cortex down through the spinal cord to control voluntary movement. These are among the longest axons in the human body, sometimes stretching a meter or more. In HSP, the axons degenerate in a length-dependent pattern, meaning the damage is worst at the ends farthest from the brain. Postmortem studies consistently find that axon loss peaks in the thoracic spinal cord for motor fibers and in the upper spinal cord and brainstem junction for the sensory fibers of the fasciculus gracilis, which carry information about limb position.1PubMed Central. Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms Autopsy analyses confirm that axonal density is reduced at every level of the corticospinal tract in HSP, but the ratio of axon counts between upper and lower levels is significantly skewed, pointing to more pronounced loss at the distal end.2PubMed. The extent of axonal loss in the long tracts in hereditary spastic paraplegia
Because the longest fibers serve the legs, leg stiffness and weakness dominate the clinical picture. The arms are typically spared or only mildly affected early on, since the motor axons reaching the arms are shorter and degenerate later, if at all. The sensory fibers that are affected carry proprioceptive information from the feet and legs, which is why many people with HSP also notice subtle problems with balance or knowing exactly where their feet are in space.
Pure Versus Complicated Forms
Clinicians divide HSP into two broad categories. In “pure” (or uncomplicated) HSP, the main symptoms are progressive spastic weakness in the legs, often accompanied by urinary urgency and mild impairment of position sense.3JAMA Neurology. The Hereditary Spastic Paraplegias: Nine Genes and Counting People with pure HSP can have a relatively normal lifespan and may walk independently for decades, though many eventually need a cane, walker, or wheelchair as stiffness progresses.
In “complicated” (or complex) HSP, spastic legs are just one piece of a broader neurological picture. Additional features can include cognitive impairment, nerve damage in the hands or feet (peripheral neuropathy), muscle wasting, difficulty with coordination (ataxia), seizures, vision problems, or structural brain abnormalities visible on MRI, such as a thin corpus callosum. Two of the most-studied complicated subtypes, SPG11 and SPG15, share a strikingly similar presentation: progressive leg spasticity alongside a thin corpus callosum, white matter changes on brain imaging, cognitive decline, and eye abnormalities.4PubMed Central. Lysosomal abnormalities in hereditary spastic paraplegia types SPG15 and SPG11 In one large series of patients with HSP and thin corpus callosum, SPG11 was the most common genetic cause and SPG15 the second most common, accounting for roughly 11.5% of cases, yet the two looked so similar clinically that genetic testing was the only reliable way to tell them apart.5PubMed. SPG15 is the second most common cause of hereditary spastic paraplegia with thin corpus callosum
The Genetic Landscape
HSP is one of the most genetically heterogeneous conditions in neurology. As of recent counts, over 80 gene locations (loci) and more than 60 corresponding genes have been linked to HSP.6PubMed. Hereditary spastic paraplegia: More than an upper motor neuron disease Mutations can be inherited in every pattern: autosomal dominant, autosomal recessive, X-linked, and even through maternal (mitochondrial) transmission. Some genes can follow more than one inheritance pattern, which complicates genetic counseling even further.
Among the autosomal dominant forms, by far the most common culprit is the SPG4 gene on chromosome 2, which encodes a protein called spastin.7PubMed. Mutation analysis of the spastin gene (SPG4) in patients in Germany with autosomal dominant hereditary spastic paraplegia Spastin’s job is to cut and remodel microtubules, the structural scaffolding inside nerve cells that also serves as the railroad for transporting cargo up and down the axon. When spastin is faulty, microtubule dynamics go haywire and cargo transport stalls, particularly in the long axons that serve the legs.
Among autosomal recessive forms, SPG11 mutations are especially significant because they cause one of the most common complicated subtypes. Recessive forms tend to start earlier in life and carry a heavier symptom burden than dominant forms, which often emerge in adolescence or adulthood with a “pure” leg-stiffness picture.
Multiple Cellular Pathways, One Clinical Outcome
Given that so many different genes can cause HSP, researchers have spent years trying to understand why the clinical result is so consistent. The answer seems to be that these genes cluster around a handful of cellular processes that are disproportionately important in very long axons.
Shaping of the endoplasmic reticulum (ER) is one major theme. The ER is a network of membrane tubes and sheets that extends through every cell, including far down into nerve axons. Several HSP-linked proteins help maintain that network’s shape. When those proteins are mutated, the ER can expand abnormally inside axons. In a mouse model combining mutations in two ER-shaping genes, electron microscopy revealed striking transverse expansions of ER inside corticospinal axons, forming a repeating ladder-like pattern not seen in normal axons.8Human Molecular Genetics. Transverse endoplasmic reticulum expansion in hereditary spastic paraplegia corticospinal axons At contact points between the ER and other organelles, protein complexes perform functions critical to neuronal survival, including calcium handling and lipid production, and HSP-causing mutations can disrupt all of these.9PubMed Central. NeurodegenERation: The Central Role for ER Contacts in Neuronal Function and Axonopathy, Lessons From Hereditary Spastic Paraplegias and Related Diseases
Microtubule dynamics represent another convergence point. Cortical neurons lacking spastin show impaired microtubule turnover, disorganized microtubule networks inside axonal swellings, and an increase in cargo that simply stalls mid-transit.10PubMed Central. Microtubule-targeting drugs rescue axonal swellings in cortical neurons from spastin knockout mice The longer the axon, the more dependent it is on efficient transport, which helps explain why the legs are hit hardest.
Lipid metabolism is a third pathway. Loss of the ER-shaping protein REEP1 in mice led to significantly reduced body fat and altered blood lipid levels, pointing to a direct role for this HSP gene in lipid regulation.11Human Molecular Genetics. Reep1 null mice reveal a converging role for hereditary spastic paraplegia proteins in lipid droplet regulation Separately, inactivation of the enzyme DDHD2, which breaks down triglycerides, substantially disrupts lipid balance and lipid droplet formation in the central nervous system.12PubMed Central. Functional Contribution of the Spastic Paraplegia-Related Triglyceride Hydrolase DDHD2 to the Formation and Content of Lipid Droplets These findings fit with the idea that long axons are especially vulnerable to any disruption in the membrane lipids they need to maintain their enormous surface area.
Mitochondrial function rounds out the picture. Mutations in the gene for paraplegin, a protein found in the mitochondrial inner membrane, cause a recessive form of HSP. Cells from people with these mutations have reduced activity of mitochondrial complex I and heightened vulnerability to oxidative stress.13Journal of Cell Biology. Loss of m-AAA protease in mitochondria causes complex I deficiency and increased sensitivity to oxidative stress in hereditary spastic paraplegia Mitochondrial abnormalities, including fragmented mitochondria and multiple deletions in mitochondrial DNA, have also been documented in another recessive subtype, SPG28.14PubMed. Mitochondrial dysfunction in hereditary spastic paraparesis with mutations in DDHD1/SPG28 And in cells carrying spastin mutations, oxidative stress markers were elevated at baseline and the cells were significantly more sensitive to hydrogen peroxide than control cells, with fewer surviving exposure and producing less energy afterward.15Scientific Reports. Mechanism of impaired microtubule-dependent peroxisome trafficking and oxidative stress in SPAST-mutated cells from patients with Hereditary Spastic Paraplegia
Getting to a Diagnosis
HSP is often described as a diagnosis of exclusion, and that description is earned. Early on, the symptoms can look like several other conditions that affect the upper motor neurons, including primary lateral sclerosis and upper-motor-neuron-dominant ALS. Telling these apart based on clinical exam alone is unreliable, particularly when symptoms start in the legs during adulthood and there is no obvious family history.16JAMA Neurology. Differentiation of Hereditary Spastic Paraparesis From Primary Lateral Sclerosis in Sporadic Adult-Onset Upper Motor Neuron Syndromes About half of HSP cases present without any other affected family member, either because of de novo mutations, recessive inheritance in small families, or variable penetrance in dominant forms.
Standard workup involves MRI of the brain and spinal cord (mainly to rule out structural causes like tumors or spinal cord compression), blood tests to exclude treatable mimics like vitamin B12 deficiency, and eventually genetic testing. Gene panel testing is now widely available, but the diagnostic yield is still limited. A molecular diagnosis is not made in most suspected cases.17The Lancet Neurology. Hereditary spastic paraplegia: clinical update That gap reflects both undiscovered genes and technical limitations of current sequencing panels.
Some imaging research is pushing toward better differentiation tools. Iron-sensitive MRI of the primary motor cortex shows a dark signal in many people with ALS and primary lateral sclerosis, but this cortical darkening appears to be rare in HSP. If validated further, this could become a useful additional clue during workup.18PubMed. Iron-sensitive MR imaging of the primary motor cortex to differentiate hereditary spastic paraplegia from other motor neuron diseases
Symptoms Beyond Walking Difficulty
Most people think of HSP as a condition that only affects walking, and even some clinicians focus exclusively on spasticity. But research consistently finds that non-motor symptoms are common and significantly affect quality of life. A study of 118 genetically confirmed SPG4 cases found that depression and pain were significantly more common than in matched controls, and all identified non-motor symptoms, including fatigue and restless legs, correlated with reduced quality of life.19PubMed. Non-motor symptoms are relevant and possibly treatable in hereditary spastic paraplegia type 4 (SPG4)
When researchers surveyed people with HSP in the Netherlands about their healthcare needs, the expected priorities were there: most wanted relief from stiffness and help with balance and walking. But more than 60% also expressed needs around pain, fatigue, emotional problems, impaired sleep, difficulty with self-care, and problems participating in daily activities.20PubMed Central. Healthcare needs, expectations, utilization, and experienced treatment effects in patients with hereditary spastic paraplegia: a web-based survey in the Netherlands A separate validation study of a patient-reported outcome measure found that, while stiffness was perceived as the most disabling symptom, weakness and imbalance followed closely, and fatigue and reduced endurance were also significant burdens.21PLoS ONE. Validation of the Italian version of a patient-reported outcome measure for Hereditary Spastic Paraplegia Bladder and sexual dysfunction are common as well, though they tend to be under-reported unless clinicians ask directly.
Current Treatment
No treatment slows or reverses the underlying nerve degeneration in HSP. Current management is entirely symptomatic, focused on reducing spasticity, preserving mobility, and addressing secondary symptoms. Oral medications like baclofen and tizanidine are first-line for spasticity. Physical therapy emphasizing stretching, strengthening, and gait training forms the backbone of ongoing care. Ankle-foot orthoses and other assistive devices are common as the disease progresses.
For people whose leg spasticity is severe and does not respond adequately to oral medication, intrathecal baclofen therapy, where a surgically implanted pump delivers baclofen directly into the spinal fluid, can be effective. One study found that spasticity scores dropped from a mean of 2.6 to 0.7 on a standard spasticity scale, and walking ability improved significantly.22PubMed. Intrathecal baclofen therapy for the symptomatic treatment of hereditary spastic paraplegia A separate audit reported improvements in spasticity measures for both the thigh and calf muscles, with all patients reporting subjective functional improvement.23Clinical Audit. Use of continuous intrathecal baclofen in hereditary spastic paraplegia The pump requires surgical maintenance and carries risks of infection and catheter malfunction, so it is typically reserved for moderate-to-severe cases.
Specialized rehabilitation strategies are being explored. A randomized trial of gait-adaptability training, which uses projected visual targets to challenge stepping accuracy on a treadmill, did not show a significant group-level improvement in obstacle navigation compared to a waiting-list control group. However, when both groups were pooled after the waiting group received training, the time needed to clear obstacles dropped by about 1.3 seconds, and the benefit persisted 15 weeks later.24PubMed Central. Gait-Adaptability Training in People With Hereditary Spastic Paraplegia: A Randomized Clinical Trial The modest result underscores how difficult it is to design effective rehabilitation for a progressive condition, but also suggests that targeted gait exercises can yield lasting, if small, functional gains.
Childhood Onset and Cerebral Palsy Mimicry
Some forms of HSP begin in early childhood and can be mistaken for cerebral palsy, since both conditions cause spastic legs in young children. This overlap matters because the treatment outlook and genetic counseling implications are very different. A number of HSP subtypes, along with certain inborn errors of metabolism, are now recognized as among the most common genetic “mimics” of cerebral palsy. Early detection of these conditions can change management, particularly where specific treatments exist for metabolic subtypes.25PubMed Central. Childhood-onset hereditary spastic paraplegia and its treatable mimics Any child with spastic legs and no clear perinatal cause, such as oxygen deprivation at birth or premature birth, should be considered for genetic testing. A family history of gait problems, even subtle ones, is an important clue that clinicians sometimes overlook.
Biomarkers on the Horizon
One of the biggest challenges in HSP research is the lack of a reliable way to measure disease activity in real time. Clinical rating scales track disability over months or years, but they are not sensitive enough to detect short-term changes, which is a problem if you want to test whether an experimental therapy is working. Blood-based biomarkers offer a possible solution.
Neurofilament light chain (NfL) is a protein released into the blood when nerve fibers are damaged. HSP patients as a group have significantly elevated blood NfL levels compared to healthy controls, and higher NfL correlates with faster disease progression as measured by clinical rating scales.26PubMed Central. Serum neurofilament light chain is increased in hereditary spastic paraplegias Longitudinal data in SPG11 and SPG15 patients confirm that NfL is significantly elevated in these complicated subtypes as well, though interestingly the levels did not predict future clinical progression in that particular cohort, and NfL showed an inverse correlation with age, suggesting the most active axonal damage may occur earlier in the disease course.27PubMed Central. Longitudinal Dynamics of Plasma Neurofilament Light Chain in Hereditary Spastic Paraplegia Type 11 (HSP-SPG11) and Type 15 (HSP-ZFYVE26) NfL is not specific to HSP — it rises in many neurodegenerative conditions — but within a confirmed HSP population, it could serve as an objective marker of ongoing nerve damage that researchers can track during clinical trials.
Stem Cell Models and Drug Discovery
Human nerve cells affected by HSP cannot easily be biopsied for study, so researchers have turned to patient-derived stem cells. Induced pluripotent stem cells (iPSCs) created from skin or blood samples of people with HSP can be coaxed into becoming the exact type of neurons affected by the disease. Neurons derived from SPG4 patients, for instance, develop significantly more axonal swellings than control neurons, and those swellings contain accumulations of mitochondria and transport proteins, recapitulating what is thought to happen in the actual disease.28Stem Cells. Loss of Spastin Function Results in Disease-Specific Axonal Defects in Human Pluripotent Stem Cell-Based Models of Hereditary Spastic Paraplegia iPSC-derived neurons from SPG3A and SPG11 patients show similar axonal defects, including impaired neurite outgrowth and reduced axonal transport.29PubMed Central. Modeling Axonal Defects in Hereditary Spastic Paraplegia with Human Pluripotent Stem Cells
These models allow researchers to screen drugs in a dish before committing to expensive animal studies. An early finding from spastin-knockout mouse neurons was that microtubule-targeting drugs could rescue the axonal swelling defect, providing proof of concept that the cellular damage is at least partially reversible.30PubMed Central. Microtubule-targeting drugs rescue axonal swellings in cortical neurons from spastin knockout mice No such drug has yet reached clinical use for HSP, but the ability to model the disease in human neurons has accelerated the search.
Gene Therapy and Disease-Modifying Research
Because HSP is caused by single-gene mutations in most subtypes, it is a natural candidate for gene therapy. The most advanced preclinical work targets SPG4, the most common dominant form. Researchers recently designed a “silence-and-replace” strategy: a viral vector carrying a small RNA molecule that shuts down the faulty spastin gene, packaged together with a healthy copy of the gene. When injected into the brains of newborn mice carrying a human spastin mutation, the treatment replaced both isoforms of endogenous spastin with healthy protein at normal levels and prevented the onset of corticospinal degeneration and gait problems that the mice would otherwise have developed in adulthood.31PubMed Central. Intracerebroventricular SPAST-AAV9 gene therapy prevents manifestation of symptoms in a mouse model of SPG4 hereditary spastic paraplegia The approach addresses both possible disease mechanisms — the possibility that the mutant protein is actively toxic and the possibility that simply having less working spastin is the problem — by silencing all copies and replacing them with a healthy version.
Drug repurposing is another active avenue. Statins are being investigated for SPG5, a recessive subtype involving abnormal cholesterol metabolism, and menatetrenone (a form of vitamin K) for a subtype linked to the ALS2 gene.32PubMed Central. Hereditary spastic paraplegia: from decades of therapy to future innovations These repurposing efforts reflect a broader shift in HSP research from purely symptomatic management toward targeting the upstream molecular defects, though all of this work remains in early stages and none has yet produced an approved disease-modifying treatment.
The fundamental challenge is HSP’s genetic fragmentation. A gene therapy that works for SPG4 does nothing for SPG11, and vice versa. Each subtype may need its own targeted approach. For ultra-rare subtypes, where perhaps only dozens of families worldwide carry a particular mutation, the economics of traditional drug development are daunting. Natural history studies that carefully document how each subtype progresses, combined with sensitive biomarkers like NfL, are considered essential groundwork so that when a therapy does reach clinical trials, researchers can actually tell whether it is working in a disease that changes slowly over years or decades.